Sat Kartar Life

Why is Sat Kartar Shopping Ltd falling/rising?

As of 11-Jun, Sat Kartar Life Ltd's stock price is declining, currently at 157.25, down 4.7% and significantly underperforming the Sensex. Despite a year-to-date gain of 9.97%, the stock is trading below all moving averages, indicating a bearish trend.

As of 11-Jun, Sat Kartar Life Ltd's stock price is falling, currently at 157.25, which represents a decrease of 7.75 or 4.7%. The stock has underperformed compared to the benchmark Sensex, which has only declined by 1.09% over the past week. Over the last month, the stock has experienced a significant drop of 20.98%, while the Sensex has fallen by just 2.75%. Year-to-date, however, the stock has shown a positive return of 9.97%, contrasting with the Sensex's decline of 11.36%. <BR><BR>Today's performance indicates that the stock is trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a bearish trend. Additionally, despite a notable increase in delivery volume by 270.97% compared to the 5-day average, the stock's overall performance today has underperformed its sector by 5.12%. This combination of factors contributes to the current decline in the stock price of Sat Kartar Life Ltd.

What does Sat Kartar do?

Sat Kartar Shopping Ltd, a Micro Cap company in the Pharmaceuticals & Biotechnology sector, was incorporated in 2012 and became a public company in 2021. It has a market cap of INR 252 Cr, with key metrics including a P/E of 15.00 and a dividend yield of 0.44%.

Overview:<BR>Sat Kartar Shopping Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated in 2012 as "Sat Kartar Shopping Private Limited" and later converted to a Public Limited Company, changing its name to Sat Kartar Shopping Limited on July 12, 2021. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 252 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 15.00<BR>Industry P/E: 34<BR>Dividend Yield: 0.44%<BR>Debt-Equity: -0.28<BR>Return on Equity: 25.51%<BR>Price-to-Book: 3.73<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Which are the latest news on Sat Kartar?

How big is Sat Kartar?

As of 10th June, Sat Kartar Shopping Ltd has a market capitalization of 252.00 Cr, classifying it as a Micro Cap company, with no valid financial data available for Net Sales and Net Profit for the latest four quarters. The balance sheet as of March 2025 shows Shareholder's Funds of 51.50 Cr and Total Assets of 63.03 Cr.

As of 10th June, <BR><BR>Market Cap: Sat Kartar Shopping Ltd has a market capitalization of 252.00 Cr, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 51.50 Cr and Total Assets of 63.03 Cr.

Who are the peers of the Sat Kartar?

Peers of Sat Kartar include Lyka Labs, Ambalal Sarabhai, Aarey Drugs, Gennex Lab., and others. Sat Kartar shows excellent management, growth, and capital structure, while its 1-year return is -28.36%, better than Lyka Labs (-37.17%) but worse than Aarey Drugs (38.60%).

Peers: The peers of Sat Kartar are Lyka Labs, Ambalal Sarabhai, Aarey Drugs, Gennex Lab., Astonea Labs, Everest Organics, BDH Industries, Zenotech Lab., Trident Lifeline, and Kerala Ayurveda.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sat Kartar, while Average management risk is found at Lyka Labs, Gennex Lab., Astonea Labs, Zenotech Lab., Trident Lifeline, and the rest. Below Average management risk is noted at Ambalal Sarabhai, Aarey Drugs, Everest Organics, and Kerala Ayurveda. In terms of growth, Excellent growth is seen at Sat Kartar, while Good growth is recorded at Gennex Lab. and Zenotech Lab., Average growth at Ambalal Sarabhai and Trident Lifeline, and Below Average growth at Lyka Labs, Aarey Drugs, Everest Organics, and Kerala Ayurveda. For capital structure, Excellent capital structure is present at Sat Kartar, Gennex Lab., BDH Industries, and Zenotech Lab., while Below Average capital structure is noted at Astonea Labs, Aarey Drugs, Everest Organics, and Kerala Ayurveda.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aarey Drugs at 38.60%, while the lowest is Lyka Labs at -37.17%. Sat Kartar's own 1-year return is -28.36%, which is better than Lyka Labs but worse than Aarey Drugs. Additionally, peers with a negative six-month return include Lyka Labs and Ambalal Sarabhai.

Is Sat Kartar overvalued or undervalued?

As of October 7, 2025, Sat Kartar is considered fairly valued with a PE ratio of 24.36, an EV to EBITDA of 15.07, and a ROE of 19.07%, making it an attractive investment compared to peers despite a recent 1-month return of -9.55%.

As of 7 October 2025, the valuation grade for Sat Kartar has moved from very attractive to attractive, indicating a shift in market perception. The company is currently considered fairly valued. Key ratios include a PE ratio of 24.36, an EV to EBITDA of 15.07, and a ROE of 19.07%. <BR><BR>In comparison to peers, Sat Kartar's PE ratio is lower than Sun Pharma's 34.6 and Divi's Lab's 70.24, which are considered expensive, while it is higher than Cipla's 22.68 and Dr. Reddy's Labs' 18.37, both of which are attractive. Despite the recent underperformance with a 1-month return of -9.55% compared to the Sensex's 1.48%, the company's strong fundamentals suggest it remains a solid investment within the pharmaceuticals and biotechnology sector.

How has been the historical performance of the Sat Kartar?

Sat Kartar reported a profit before tax of Rs 8.00 crore for the year ending March 2024, with a net cash inflow of Rs 1.00 crore, resulting in a closing cash balance of Rs 2.00 crore despite cash outflows from investing and financing activities.

Answer:<BR>The historical performance of Sat Kartar shows a profit before tax of Rs 8.00 crore for the year ending March 2024. After accounting for adjustments of Rs 1.00 crore, the cash flow after changes in working capital stands at Rs 10.00 crore. The cash flow from operating activities is recorded at Rs 7.00 crore, while cash flow from investing and financing activities both show outflows of Rs 2.00 crore each. This results in a net cash inflow of Rs 1.00 crore, leading to a closing cash and cash equivalent balance of Rs 2.00 crore.<BR><BR>Breakdown:<BR>In the standalone cash flow results for March 2024, Sat Kartar reported a profit before tax of Rs 8.00 crore, with adjustments bringing the cash flow after changes in working capital to Rs 10.00 crore. The cash flow from operating activities was positive at Rs 7.00 crore, indicating healthy operational performance. However, the company experienced cash outflows from both investing and financing activities, each amounting to Rs 2.00 crore. Despite these outflows, Sat Kartar achieved a net cash inflow of Rs 1.00 crore, resulting in a closing cash and cash equivalent balance of Rs 2.00 crore, reflecting a modest liquidity position.

Who are the top shareholders of the Sat Kartar?

The top shareholders of Sat Kartar include Ajooni Wellness Private Limited with 36.28%, eight Foreign Institutional Investors holding 6.31%, and Shreya Jain as the highest public shareholder at 3.56%. Individual investors own 17.81% of the shares, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Sat Kartar include Ajooni Wellness Private Limited, which holds the highest stake at 36.28%. Additionally, there are eight Foreign Institutional Investors (FIIs) collectively holding 6.31% of the company. The highest public shareholder is Shreya Jain, with a holding of 3.56%. Individual investors collectively own 17.81% of the shares. There are no pledged promoter holdings, and no mutual funds are currently holding shares in the company.

When is the next results date for Sat Kartar?

No Upcoming Board Meetings

Has Sat Kartar declared dividend?

No Dividend History Available